These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 29386395)

  • 1. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8
    Jevtovic A; Pantic J; Jovanovic I; Milovanovic M; Stanojevic I; Vojvodic D; Arsenijevic N; Lukic ML; Radosavljevic GD
    Cancer Immunol Immunother; 2020 Aug; 69(8):1461-1475. PubMed ID: 32285171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
    Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
    Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
    Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M
    Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8
    Jiao JZ; Zhang Y; Zhang WJ; He MD; Meng M; Liu T; Ma QL; Xu Y; Gao P; Chen CH; Zhang L; Pi HF; Deng P; Wu YZ; Zhou Z; Yu ZP; Deng YC; Lu YH
    Acta Pharmacol Sin; 2024 Jul; 45(7):1492-1505. PubMed ID: 38538718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
    Freimark BD; Gong J; Ye D; Gray MJ; Nguyen V; Yin S; Hatch MM; Hughes CC; Schroit AJ; Hutchins JT; Brekken RA; Huang X
    Cancer Immunol Res; 2016 Jun; 4(6):531-40. PubMed ID: 27045021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
    Singh M; Vianden C; Cantwell MJ; Dai Z; Xiao Z; Sharma M; Khong H; Jaiswal AR; Faak F; Hailemichael Y; Janssen LME; Bharadwaj U; Curran MA; Diab A; Bassett RL; Tweardy DJ; Hwu P; Overwijk WW
    Nat Commun; 2017 Nov; 8(1):1447. PubMed ID: 29129918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
    Eschweiler S; Clarke J; Ramírez-Suástegui C; Panwar B; Madrigal A; Chee SJ; Karydis I; Woo E; Alzetani A; Elsheikh S; Hanley CJ; Thomas GJ; Friedmann PS; Sanchez-Elsner T; Ay F; Ottensmeier CH; Vijayanand P
    Nat Immunol; 2021 Aug; 22(8):1052-1063. PubMed ID: 34168370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
    Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
    Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.